Stockreport

R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF People with failing kidneys deal with a host of health issues, among them a complication that drives up phosphorus levels so high it can weaken bones and damage the hea [Read more]